B7-H3 (CD276): A Structurally Unique Immune Checkpoint Molecule and Tumor Therapeutic Target

Author: Senior Product Manager of UA Views：12

This article focuses on the molecular structure, expression distribution, and tumor immunological functions of B7-H3 (CD276), systematically elaborating its composition as a type I transmembrane protein with extracellular immunoglobulin domains and the characteristics of its intracellular region lacking clear signaling motifs, analyzing its distribution pattern of widespread mRNA expression but relatively restricted protein expression as well as its association with overexpression and poor prognosis in multiple tumors, and exploring the development logic of therapeutic strategies targeting B7-H3 under the condition that its receptor has not yet been clearly identified.

Recent Advances
Product Information

Recent Advances

B7-H3 (CD276): An Immune Checkpoint Molecule with a Unique Structure and a Tumor Therapeutic Target

Brief introduction: This article focuses on the molecular structure, expression distribution, and tumor immunological functions of B7-H3 (CD276). It systematically describes the composition of the extracellular immunoglobulin domains of this type I transmembrane protein and the characteristics of its intracellular region, which lacks clear signaling motifs. It analyzes the distribution pattern of broad mRNA expression but relatively restricted protein expression, as well as the association between its overexpression and poor prognosis in various tumors, and discusses the logic of developing therapeutic strategies targeting B7-H3 under the condition that its receptor has not yet been identified.

I. Molecular Structure and Signaling Characteristics of B7-H3.

B7-H3, also known as CD276, is a type I transmembrane protein. In terms of protein structure, its extracellular region contains two pairs of identical immunoglobulin variable and constant regions, and its intracellular region is very short, with no clear signaling motifs. This structural feature has important functional implications: unlike those checkpoint molecules whose intracellular regions carry classic inhibitory motifs such as ITIM or ITSM, B7-H3 does not possess the intracellular structural basis for directly transmitting inhibitory signals, and its functional realization is more likely to depend on cis/trans interactions with as-yet-unidentified receptors or other membrane molecules. Therefore, the mechanism of B7-H3-mediated immune regulation still has significant knowledge gaps at the molecular level, which is also one of the core issues that research on this target has long faced.

II. Expression Distribution Characteristics of B7-H3: Broad Transcription but Restricted Protein.

The mRNA expression of B7-H3 is relatively broad, but protein expression is relatively restricted to non-immune cells such as resting fibroblasts, endothelial cells, osteoblasts, and amniotic fluid stem cells, as well as the surface of induced antigen-presenting cells and NK cells. This distribution pattern of “broad transcription but restricted protein” suggests that B7-H3 protein expression is strictly regulated at the post-transcriptional or translational level, and also means that judging its functional expression status based solely on mRNA data may be biased. In normal tissues, B7-H3 protein expression is limited to specific non-immune cells and induced immune cells, which provides a relatively restricted normal tissue expression background for its use as a tumor target.

III. Overexpression of B7-H3 in Tumors and Its Association with Prognosis.

Many studies have revealed that B7-H3 is overexpressed in a variety of tumors, including melanoma, leukemia, breast cancer, prostate cancer, colorectal cancer, and other tumors, and its expression level is closely associated with poor patient prognosis and poor clinical outcomes, suggesting that it participates in tumor immune evasion. Although its molecular mechanism is not yet clear, as a possible immune checkpoint molecule, it is a promising target for tumor immunotherapy. From the perspective of clinical relevance, the stable association between B7-H3 overexpression and poor prognosis provides epidemiological support for its use as a therapeutic target; while the unclear mechanism means that the design of targeting strategies cannot simply apply the “blocking ligand-receptor binding” paradigm of classic checkpoint inhibitors.

IV. Development Logic of Therapeutic Strategies Targeting B7-H3.

Based on the successful clinical experience of many immune checkpoint (CTLA-4, PD-1, PD-L1) inhibitor drugs, it is highly necessary to develop monoclonal antibodies targeting B7-H3 with therapeutic prospects. However, because the receptor of B7-H3 is currently unclear, it is still difficult to develop neutralizing blocking antibodies. This dilemma has directly led to the differentiation of targeting strategies: since immune suppression cannot be relieved by blocking ligand-receptor interactions, researchers have shifted their approach to using the high expression of B7-H3 on the surface of tumor cells itself as a targeting anchor, achieving tumor-specific killing through modalities such as antibody-drug conjugates, bispecific antibodies, and CAR-T cells, rather than relying on blockade of signaling pathways. In other words, the development logic of B7-H3 is closer to “expression-guided delivery and killing” rather than “pathway-guided functional inhibition,” and this paradigm shift is a key feature that distinguishes this target from classic immune checkpoints.

V. Conclusion.

As a type I transmembrane protein, B7-H3 (CD276) has become a highly promising target in the field of tumor immunotherapy by virtue of its extracellular structure composed of two pairs of identical immunoglobulin variable and constant regions, its short intracellular region lacking clear signaling motifs, its distribution characteristics of broad mRNA expression but relatively restricted protein expression, and its clinical association with overexpression and close correlation with poor prognosis in multiple tumors such as melanoma, leukemia, breast cancer, prostate cancer, and colorectal cancer.

In basic research and targeted drug development related to B7-H3, high-quality recombinant B7-H3 protein is a core tool for analyzing its domain characteristics, evaluating the binding activity of targeting antibodies, and conducting receptor identification studies. The His tag facilitates efficient purification by immobilized metal affinity chromatography and enables detection and capture with anti-His tag antibodies. To meet the needs of B7-H3 functional research and tumor immunotherapy drug development, UA provides B7-H3/CD276 His Tag Protein, Human. This product is suitable for applications such as binding activity analysis of B7-H3 with targeting antibodies, studies of interactions mediated by the B7-H3 extracellular immunoglobulin domains, in vitro screening of antibody-drug conjugates and bispecific antibodies targeting B7-H3, and identification and validation of unknown B7-H3 receptors.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next